|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Southwest Oncology Group National Cancer Institute (NCI) |
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00066742 |
Purpose
RATIONALE: Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Tirapazamine may make the tumor cells more sensitive to chemotherapy and radiation therapy. Combining chemotherapy and radiation therapy with tirapazamine may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving tirapazamine together with cisplatin, etoposide, and radiation therapy works in treating patients with limited-stage small cell lung cancer.
| Condition | Intervention | Phase |
|
Lung Cancer |
Drug: cisplatin Drug: etoposide Drug: tirapazamine Procedure: radiation therapy |
Phase II |
| MedlinePlus related topics: | Cancer Lung Cancer |
| Drug Information available for: | Etoposide Cisplatin Etoposide phosphate Tirapazamine |
| Study Type: | Interventional |
| Study Design: | Treatment, Open Label |
| Official Title: | A Phase II Study Of Tirapazamine (NSC-130181)/Cisplatin/Etoposide And Concurrent Thoracic Radiotherapy For Limited Stage Small Cell Lung Cancer |
| Estimated Enrollment: | 85 |
| Study Start Date: | September 2003 |
OBJECTIVES:
OUTLINE: This is a multicenter study.
Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed every 2-3 months for 2 years and then every 6 months for 1 year.
PROJECTED ACCRUAL: A total of 30-85 patients will be accrued for this study within 17 months.
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed limited stage small cell lung cancer (SCLC)
Measurable or non-measurable disease by CT scan, MRI, or x-ray
No malignant pericardial or pleural effusion*, defined as 1 of the following:
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
Contacts and Locations![]() |
Show 134 Study Locations |
| Southwest Oncology Group |
| National Cancer Institute (NCI) |
| Study Chair: | Quynh-Thu X. Le, MD | Stanford University |
| Investigator: | Stephen K. Williamson, MD | University of Kansas |
| Investigator: | Primo N. Lara, MD | University of California, Davis |
| Investigator: | Zelanna Goldberg, MD | University of California, Davis |
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
|
Le Q, Moon J, Redman M, et al.: SWOG 0222: A phase II study of tirapazamine (NSC-130181, TPZ)/cisplatin/etoposide (PE) and concurrent thoracic radiotherapy (TRT) for limited stage small-cell lung cancer (LSCLC). [Abstract] J Clin Oncol 26 (Suppl 15): A-7523, 2008.
  |
| Study ID Numbers: | CDR0000318805, SWOG-S0222 |
| First Received: | August 6, 2003 |
| Last Updated: | July 23, 2008 |
| ClinicalTrials.gov Identifier: | NCT00066742 |
| Health Authority: | United States: Federal Government |
|
|
|
|
|